CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Key Points

• HC Wainwright raised its price target to $17 (from $10) and maintained a "buy" rating, implying roughly a 110% upside, while overall analyst sentiment is bullish (eight Buys, one Hold; consensus target $10.25).
• Positive Phase 1 data for varsetatug masetecan (confirmed response rates of 32% and 20%, estimated PFS ~7 months and manageable toxicity) is the primary catalyst, with mid-year FDA interactions and combination studies planned to discuss potential registrational plans.
• The company reported a disappointing Q4 (GAAP loss $0.22/sh vs. $0.08 expected and revenue $0.66M vs. ~$7.33M expected), which raises near-term concerns about cash burn and financing despite a recent sharp share-price spike and heavy trading volume.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) had its price target hoisted by equities research analysts at HC Wainwright from $10.00 to $17.00 in a research report issued on Monday,Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. HC Wainwright's price target indicates a potential upside of 110.24% from the company's current price.

Several other research analysts also recently commented on the company. Oppenheimer reissued an "outperform" rating on shares of CytomX Therapeutics in a research note on Monday. Piper Sandler raised their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an "overweight" rating in a research note on Tuesday, January 20th. Barclays upped their price objective on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 4th. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $7.00 to $12.00 in a research note on Monday. Finally, Guggenheim restated a "buy" rating and issued a $10.00 target price on shares of CytomX Therapeutics in a research report on Monday, March 9th. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, CytomX Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $10.25.

CytomX Therapeutics Price Performance

Shares of CTMX stock traded up $3.41 on Monday, hitting $8.09. 89,304,699 shares of the company's stock were exchanged, compared to its average volume of 4,848,602. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $8.21. The stock has a market cap of $1.37 billion, a P/E ratio of 20.06 and a beta of 2.44. The company has a 50 day moving average of $5.19 and a 200 day moving average of $4.04.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company's stock worth $28,000 after buying an additional 3,000 shares during the period. Farther Finance Advisors LLC acquired a new position in CytomX Therapeutics in the 3rd quarter valued at approximately $25,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of CytomX Therapeutics during the fourth quarter valued at $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of CytomX Therapeutics during the third quarter valued at $34,000. Finally, May Hill Capital LLC acquired a new position in shares of CytomX Therapeutics during the fourth quarter worth $46,000. Institutional investors and hedge funds own 67.77% of the company's stock.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 dose-expansion data for varsetatug masetecan showed confirmed response rates of 32% (10 mg/kg Q3W) and 20% (8.6 mg/kg Q3W) with estimated PFS ~7 months and manageable grade 3 diarrhea (~10%); company is targeting mid-year FDA interactions to discuss a potential registrational trial and has initiated combination studies — this clinical readout is the primary catalyst for the stock move. CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
• Neutral Sentiment: Company published its 2025 financial results and a business update and hosted a conference call/slide deck providing context on the program timelines and cash/operating outlook — useful for judging runway and development timing. CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst previews and coverage highlighted the Q4 print and the clinical readout as the key near-term drivers; keep an eye on any updated analyst notes or revised models following the results. CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
• Negative Sentiment: Q4 results disappointed: GAAP loss of $0.22/sh vs. Zacks consensus loss of $0.08, and revenue of $0.66M missed expectations (~$7.33M). The financial miss raises near-term uncertainty around commercial/partner revenues and will push focus to cash burn and financing needs. CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.